Zobrazeno 1 - 6
of 6
pro vyhledávání: '"fully human albumin binding (FHAB) domain"'
Autor:
John K. Cini, Richard T. Kenney, Susan Dexter, Stephen J. McAndrew, Rukiye-Nazan Eraslan, Rich Brody, Darrel J. Rezac, Rebecca Boohaker, Suzanne E. Lapi, Pankaj Mohan
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundCytokines have been promising cancer immunotherapeutics for decades, yet only two are licensed to date. Interleukin-12 (IL-12) is a potent regulator of cell-mediated immunity that activates NK cells and interferon-γ (IFNγ) production. It
Externí odkaz:
https://doaj.org/article/438bbbcb4fa04e72a0a4640f320246d0
Autor:
Richard T. Kenney, John K. Cini, Susan Dexter, Manuel DaFonseca, Justus Bingham, Isabelle Kuan, Sant P. Chawla, Thomas M. Polasek, Jason Lickliter, Philip J. Ryan
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundThe benefits of recombinant interleukin-12 (rIL-12) as a multifunctional cytokine and potential immunotherapy for cancer have been sought for decades based on its efficacy in multiple mouse models. Unexpected toxicity in the first phase 2 s
Externí odkaz:
https://doaj.org/article/9baead1eb8e549ccaed6f20a613f9c70
Autor:
John K. Cini, Susan Dexter, Darrel J. Rezac, Stephen J. McAndrew, Gael Hedou, Rich Brody, Rukiye-Nazan Eraslan, Richard T. Kenney, Pankaj Mohan
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundThe potential synergy between interleukin-12 (IL-12) and IL-15 holds promise for more effective solid tumor immunotherapy. Nevertheless, previous clinical trials involving therapeutic cytokines have encountered obstacles such as short pharm
Externí odkaz:
https://doaj.org/article/ec5b713791af4cd19df56d27a6cab5cc
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Cini JK; Sonnet BioTherapeutics, Inc., Princeton, NJ, United States., Kenney RT; Sonnet BioTherapeutics, Inc., Princeton, NJ, United States., Dexter S; Sonnet BioTherapeutics, Inc., Princeton, NJ, United States., McAndrew SJ; Sonnet BioTherapeutics, Inc., Princeton, NJ, United States., Eraslan RN; Disease Modeling and Oncology, Invivotek, Hamilton, NJ, United States., Brody R; InfinixBio, Inc., Athens, OH, United States., Rezac DJ; Latham Biopharm Group, Inc., Elkridge, MD, United States., Boohaker R; Southern Research, Birmingham, AL, United States., Lapi SE; Radiology, Chemistry, and Biomedical Engineering, University of Alabama, Birmingham, AL, United States., Mohan P; Sonnet BioTherapeutics, Inc., Princeton, NJ, United States.
Publikováno v:
Frontiers in immunology [Front Immunol] 2024 Dec 04; Vol. 15, pp. 1493257. Date of Electronic Publication: 2024 Dec 04 (Print Publication: 2024).